Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3109276 | 0.78 | TNK2 (0.46) | DHFRMEN1KMT2AKDM4CTNK2 | |
| SCHEMBL566012 | 0.78 | HSD11B1 (0.39) | DHFRMEN1KMT2AKDM4CTNK2 | |
| SCHEMBL30918744 | 0.76 | ALDH1A1 (0.40) | DHFRMEN1KMT2AKDM4CTNK2 | |
| SCHEMBL5863927 | 0.75 | HPGD (0.40) | DHFRMEN1KMT2ATNK2NPC1 | |
| SCHEMBL29653682 | 0.75 | TYR (0.48) | DHFRMEN1KMT2ATNK2HSD11B1 | |
| SCHEMBL1134318 | 0.75 | TYR (0.48) | DHFRMEN1KMT2ATNK2HSD11B1 | |
| SCHEMBL29394265 | 0.73 | ALDH1A1 (0.54) | NPC1RAB9APTPN1L3MBTL1 | |
| SCHEMBL5863561 | 0.73 | ALDH1A1 (0.54) | NPC1RAB9APTPN1L3MBTL1 | |
| SCHEMBL28518072 | 0.73 | POLB (0.44) | DHFRMEN1KMT2AKDM4CTNK2 | |
| SCHEMBL15068100 | 0.73 | MEN1 (0.45) | DHFRMEN1KMT2AKDM4CTNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2797889-A1 | NOVEL ARYLALKENE DERIVATIVES AND USE THEREOF AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | Centaurus Biopharma Co., Ltd. (CN) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013097773-A1 | NOVEL ARYLALKENE DERIVATIVES AND USE THEREOF AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2013-07-04 | — | — | WO | disclosed |